 To compare the effectiveness, in a real world practice setting in tier 2 cities of China, of Entecavir ETV monotherapy and Lamivudine LAM based therapies including LAM monotherapy, de novo LAM Adefovir ADV combination, and early add-on of ADV among chronic hepatitis B CHB patients who are naive to NUC at enrollment to this study 